Trademark: 79066733
Word
CHARIOTEER
Status
Registered
Status Code
706
Status Date
Tuesday, July 30, 2019
Serial Number
79066733
Registration Number
3722653
Registration Date
Tuesday, December 8, 2009
Mark Type
3000
Filing Date
Friday, December 12, 2008
Published for Opposition
Tuesday, September 22, 2009

Trademark Owner History

Classifications
5 Antipyretyc, analgesic and anti-inflammatory active pharmaceutical ingredient, namely, naproxen, naproxen sodium, naproxen celecoxib, nimesulide, aceclofenac, sulindac, ibuprofen, fenoprofen, ketoprofen, celecoxib, nimesulide, aceclofenac; anti-inflammatory active pharmaceutical ingredient, namely, naproxen nitroxyalkylesters; antipyretic and analgesic active pharmaceutical ingredient, namely, aspirin, acetaminophen, propyphenazone; antipyretic and analgesic, antithrombotic active pharmaceutical ingredient, namely, indomethacin; analgesic active pharmaceutical ingredient, namely, eptazocine, ketorolac tromethamine; antipyretic, analgesic active pharmaceutical ingredient, namely, propyphenazone; anti-inflammatory and anti-virus active pharmaceutical ingredient, namely, amantadine hydrochloride; treating rheumatoid arthritis active pharmaceutical ingredient, namely, flurbiprofen, meloxicam, phenylbutazone; anti-platelet aggregation active pharmaceutical ingredient, namely, clopidogrel hydrogen sulfate; anti-platelet drugs active pharmaceutical ingredient, namely, prasugrel; anti-cancer active pharmaceutical ingredient, namely, topotecan hydrochloride, ifosfamide, mesna, irinotecan, camptothecin, 7-ethyl-10-hydrol-camptothecin, docetaxel; treating iodine deficiency active pharmaceutical ingredient, namely, iodine; anti-goitre expectoration and active pharmaceutical ingredient, namely, potassium iodide; treating supraventricular arrhythmia, typical angina and variant angina active pharmaceutical ingredient, namely, diltiazem; anti-hepatitis B virus active pharmaceutical ingredient, namely, adefovir dipivoxil, lamivudine, telbivudine, clevudine; anti-urogenital system disease active pharmaceutical ingredient, namely, phenazopyridine hydrochloride; anti-virus active pharmaceutical ingredient, namely, acyclovir, acyclovir sodium, penciclovir, zidovudine, ganciclovir, ganciclovir sodium, famciclovir, valaciclovir hydrochloride, valganciclovir hydrochloride, ribavirin, 6-deoxyacyclovir, polyinosinic polycytidylic acid, interferons, adenine, farmivisen, docosanol, zanamvir, oseltamivir, indinavir, ritonavir, nelfinavir, delavirdine, efavirenz, ainprenavir, lopinavir, cidofovir, imiquimod, didanosine, foscarnet sodium, penciclovir sodium, stavudine, abacavir, tenofovir disoproxil, emdtricitabine, brivudine, amprenavir, rimantadine; expectorant active pharmaceutical ingredient, namely, fudosteine, carbocisteine; anti-hypertension active pharmaceutical ingredient, namely, valsartan, losartan, irbesartan, tasosartan, candesartan, telmisartan, eprosartan, olmesartan; anxiolytic active pharmaceutical ingredient, namely, brofoxine; treating coronary heart disease active pharmaceutical ingredient, namely, dipyridamole; immunosuppressive active pharmaceutical ingredient, namely, tacrolimus; immunosuppressive agents active pharmaceutical ingredient, namely, sirolimus; treating cardiac and cerebrovascular disease active pharmaceutical ingredient, namely, nicergoline; treating coronary heart disease active pharmaceutical ingredient, namely, isosorbide mononitrate; anti-obesity active pharmaceutical ingredient, namely, orlistat; antipsychotic active pharmaceutical ingredient, namely, perazine maleate, carisoprodol; anti-leprosy disease active pharmaceutical ingredient, namely, thalidomide; anti-vitamin deficiency active pharmaceutical ingredient, namely, folic acid, dexpanthenol; anti-megaloblastic anemia active pharmaceutical ingredient, namely, calcium levofolinate; antithrombotic active pharmaceutical ingredient, namely, ticlopidine hydrochloride; anti-rejection active pharmaceutical ingredient, namely, rapamycin, mizoribine, mycophenolic acid, mycophenolate mofetil, mycophenolate sodium, clarithromycin, daptomycin, mupirocin, ertapenem, doripenem, biapenem, meropenem, imipenem, faropenem, aztreonam, benflumetol, mupirocin, caspofungin; treating diabetes mellitus active pharmaceutical ingredient, namely, metformin, voglibose; antioxidant, treatment heart disease and anti-hypertension active pharmaceutical ingredient, namely, coenzyme Q10; treating brain edema and glaucoma active pharmaceutical ingredient, namely, isosorbide; anti-aids active pharmaceutical ingredient, namely, nevirapine
Color is not claimed as a feature of the mark.
The mark consists of a stylized wheel and axle with two Chinese characters and the wording "CHARIOTEER" appearing beneath the design.
The non-Latin characters in the mark transliterate to "CHE TOU" and this means "charioteer" and "the front of a vehicle" in English.

Trademark Events
Jul 30, 2019
Notice Of Acceptance Of Sec. 71 - E-Mailed
Jul 30, 2019
Registered-Sec.71 Accepted
Jul 26, 2019
Teas Change Of Correspondence Received
Jul 26, 2019
Teas Section 71 Received
Dec 28, 2018
International Registration Renewed
Dec 8, 2018
Courtesy Reminder - Sec. 71 (10-Yr) E-Mailed
Jan 15, 2015
Notice Of Acceptance Of Sec. 71 - E-Mailed
Jan 15, 2015
Registered-Sec.71 Accepted
Jan 15, 2015
Case Assigned To Post Registration Paralegal
Dec 11, 2014
Teas Section 71 Received
Dec 11, 2014
Teas Change Of Correspondence Received
Jan 30, 2013
Final Decision Transaction Processed By Ib
Apr 1, 2010
Final Disposition Notice Sent To Ib
Apr 1, 2010
Final Disposition Processed
Mar 9, 2010
Final Disposition Notice Created, To Be Sent To Ib
Dec 8, 2009
Registered-Principal Register
Sep 22, 2009
Published For Opposition
Sep 2, 2009
Notice Of Publication
Aug 18, 2009
Law Office Publication Review Completed
Aug 18, 2009
Assigned To Lie
Aug 11, 2009
Approved For Pub - Principal Register
Jul 20, 2009
Teas/Email Correspondence Entered
Jul 15, 2009
Correspondence Received In Law Office
Jul 15, 2009
Teas Response To Office Action Received
May 22, 2009
Refusal Processed By Ib
Apr 27, 2009
Non-Final Action Mailed - Refusal Sent To Ib
Apr 27, 2009
Refusal Processed By Mpu
Apr 26, 2009
Non-Final Action (Ib Refusal) Prepared For Review
Apr 25, 2009
Non-Final Action Written
Apr 21, 2009
Application Filing Receipt Mailed
Apr 17, 2009
Assigned To Examiner
Apr 17, 2009
New Application Office Supplied Data Entered In Tram
Apr 16, 2009
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24